Comparative studies on properties of unfractionated and low molecular weight heparin.
LMW heparin (FR-860) produced by depolymerization of unfractionated heparin with dinitric acid was used to investigate clinical effects in healthy volunteers. The results were as follows: 1. Subjective symptoms, physiologic studies, blood examinations, blood chemistry, and urinary chemistry tests were not changed. 2. Two of five volunteers who received unfractionated heparin (H-25) and two of five who received LMW heparin (F-50) manifested petechiae at the injection sites. These bleedings were dose dependent. 3. The effect on APTTs and thrombin times was less evident with F-25 and F-35 than with H-25; F-50 showed greater prolongation than H-25. 4. The half-life of LMW heparin was 1.5 to 1.8 hours; unfractionated heparin had 0.68 hours. 5. No changes were observed in the levels of AT III, fibrinogen, and FDP. 6. Platelet aggregation rates induced by 1.0 microM ADP were less affected by LMW heparin than by unfractionated heparin. 7. Platelet factor 4 levels increased markedly, but to a lesser extent with LMW heparin than with unfractionated heparin. These results are due to its mobilization from the vessel wall. No changes were observed in beta-thromboglobulin levels. 8. Fatty acid analysis (LPL and HTGL) was less affected by LMW heparin than by unfractionated heparin.
Sakuragawa
N
N
Department of Clinical Laboratory Medicine, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Japan.
Takahashi
K
K
D000328:Adult; D001780:Blood Coagulation Tests; D005227:Fatty Acids / Q000378:metabolism; D006493:Heparin / Q000009:adverse effects* / Q000493:pharmacokinetics; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects* / Q000493:pharmacokinetics; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D010979:Platelet Function Tests
D005227:Fatty Acids; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin